(CercleFinance.com) – Innate Pharma today announces its first-half results. The company reports a cash position of €158.2 million as of June 30, 2022. The group made a net profit of €6.3 million.
Operating income relating to continuing activities amounted to €45.6m (€14.7m for the first half of 2021).
Operating expenses relating to continuing activities amounted to €37.1m (€33.9m for the first half of 2021), of which 67.3% (€25m) was devoted to R&D.
The financial result shows a net loss of €2.1m for the first half of 2022 (net gain of €1.7m for the first half of 2021).
Note that Monalizumab and IPH5201, developed with AstraZeneca, have advanced to Phase 3 and Phase 2 clinical trials, triggering $55M in milestone payments.
‘Thanks to our solid cash position, our portfolio continued to enjoy good momentum. We look forward to the next results of the TELLOMAK Phase 2 study for lacutamab and the progress of the ANKETTM platform in the second half of the year,” commented Mondher Mahjoubi, Chairman of the Management Board of Innate Pharma.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about INNATE PHARMA in real time: